Human CXCL2 Antibody from BIOLEGEND

CXCL2 is an ELR CXC chemokine, and it is structurally and functionally related to GRO1 (CXCL1), GRO3 (CXCL3), and interleukin-8 (CXCL8). CXCL2 binds to the CXCR2 receptor; this receptor is shared with other ELR CXC chemokines (CXCL1, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8). CXCL2 is highly expressed in esophageal squamous cell carcinoma (ESCC), and it has been detected in serum of patients with this disease. CXCL1, CXCL2 and CXCL3 have all been shown to be highly expressed in patients with malignant melanoma. In addition, CXCL2 and CXCL1 are upregulated in the central nervous system in multiple sclerosis (MS) and in the animal model of experimental autoimmune encephalomyelitis (EAE). In EAE, it has been shown that transfer of encephalitogenic CD4+ Th17 cells induce CXCL1 and CXCL2 transcription in the spinal cords of naïve, syngeneic recipients. IL-17 is a potent inducer of ELR+ CXC chemokines in MS and EAE. It has been proven that CXCL1 and CXCL1 are upregulated in the preclinical and clinical stages of EAE.